Gastroenterology
From the Journals
Many Patients With Cancer Visit EDs Before Diagnosis
Factors associated with an increased likelihood of an ED visit ahead of diagnosis included having certain cancers, living in rural areas, and...
Conference Coverage
Short-Course Vasoconstrictors After EVL: Time for a New Standard of Care?
“This approach would allow earlier discharge from the hospital and reduce the risk of adverse events,” said Dr. Sushrut Ingawale.
From the Journals
More evidence shows COVID-19’s link to risk for autoimmune disease
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several...
From the Journals
ChatGPT may aid decision-making in the ED for acute ulcerative colitis
Chatbot provided a detailed answer depicting severity of every variable of the criteria and an overall severity classification.
News from the FDA/CDC
FDA gives semaglutide two drug safety–related label changes
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
From the Journals
EoE: One-food elimination works as well as six-food elimination
“The takeaway message is that one-food (milk) elimination is an effective treatment and a reasonable first-line treatment for EoE.”
From the Journals
Celiac disease appears to double COVID-19 hospitalization risk
“To our knowledge this is the first study that demonstrated a vaccination effect on mitigation of the risk of hospitalization in celiac disease...
Commentary
Must-read acute care medicine articles from 2022
“When 2022 began, we started seeing some light at the end of the COVID-19 tunnel.”
From the Journals
Acute hepatic porphyrias no longer as rare as previously thought
Recent treatment advances have improved the outlook for patients with acute hepatic porphyrias.
Feature
A patient named ‘Settle’ decides to sue instead
His suit seeks not only compensatory damages and other relief but also punitive damages.
From the Journals
Vonoprazan triple therapy most cost-effective for H. pylori: Study
Rifabutin triple therapy (Talicia) is the second most cost-effective strategy for H. pylori eradication.